Clear2Cure is a biotech spin-off from Utrecht University, the Netherlands. We are developing Clearbodies®, a novel class of bispecific antibody-derived therapeutics. They are designed to capture disease targets and direct them to the cell’s natural degradation system, the lysosome. Subsequently, the target is rapidly cleared for efficient and sustained therapeutic effects. With our proprietary, modular platform, we are building a preclinical pipeline targeting diseases in the infection and immunity space that were previously considered undruggable or are poorly addressed by existing therapies. Our mission is to transform treatment options for patients facing severe infections, inflammatory disorders, and beyond.